gms | German Medical Science

70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12.05. - 15.05.2019, Würzburg

Artikel

Artikel empfehlen

CUSP9* elicits significant anti-cancer activity against glioblastoma cells in vitro

CUSP9* hat signifikante inhibierende Wirkungen auf Glioblastomzellen in vitro

Meeting Abstract

Suche in Medline nach

  • Marc-Eric Halatsch - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Richard Eric Kast - IIAIGC Study Center, Burlington, VT, United States
  • Annika Dwucet - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Tim Heiland - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Markus David Siegelin - Columbia University Medical Center, Department of Pathology and Cell Biology, New York, NY, United States
  • Christian Rainer Wirtz - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • presenting/speaker Georg Karpel-Massler - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie. Würzburg, 12.-15.05.2019. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocP052

doi: 10.3205/19dgnc390, urn:nbn:de:0183-19dgnc3903

Veröffentlicht: 8. Mai 2019

© 2019 Halatsch et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: Drug repurposing is a strategy to safely accelerate the clinical application of therapeutics that provide anti-cancer activity. CUSP9* represents such a therapeutic regime which includes nine repurposed drugs along with low-dose metronomic temozolomide. In this work, we examined the biological activity of the CUSP9* regimen in an in vitro setting of glioblastoma.

Methods: MTT and soft-agar assays were used to examine cellular proliferation. Staining for Annexin V/PI and Western blotting were used to examine pro-apoptotic effects. A spheroid assay was performed to assess effects of the treatment on three-dimensional growth. Time-lapse microscopy, radius and transwell assays were performed to examine anti-migratory effects.

Results: Treatment with CUSP9* exerted profound anti-proliferative activity and inhibited anchorage-independent growth among a broad panel of established, primary cultured and glioblastoma stem-like cells. These effects were accompanied by enhanced apoptosis as indicated by an increased fraction of Annexin V-positive cells and enhanced caspase-3 cleavage. Moreover, CUSP9* led to significantly decreased 3-dimensional tumor formation. In addition, non-directed and directed movement of glioblastoma cells were significantly impaired following CUSP9* treatment.

Conclusion: se data suggest that CUSP9* has potent anti-cancer activity in vitro which is currently further explored by a clinical trial being conducted at our institution (NCT02770378).